- •Preface and Acknowledgments
- •Contents
- •Contributors
- •1: Embryology for Urologists
- •Introduction
- •Renal Development
- •Pronephros
- •Mesonephros
- •Metanephros
- •Development of the Collecting System
- •Critical Steps in Further Development
- •Anomalies of the Kidney
- •Renal Agenesis
- •Renal Aplasia
- •Renal Hypoplasia
- •Renal Ectopia
- •Renal Fusion
- •Ureteral Development
- •Anomalies of Origin
- •Anomalies of Number
- •Incomplete Ureteral Duplication
- •Complete Ureteral Duplication
- •Ureteral Ectopia
- •Embryology of Ectopia
- •Clinical Correlation
- •Location of Ectopic Ureteral Orifices – Male (in Descending Order According to Incidence)
- •Symptoms
- •Ureteroceles
- •Congenital Ureteral Obstruction
- •Pipestem Ureter
- •Megaureter-Megacystis Syndrome
- •Prune Belly Syndrome
- •Vascular Ureteral Obstructions
- •Division of the Urogenital Sinus
- •Bladder Development
- •Urachal Anomalies
- •Cloacal Duct Anomalies
- •Other Bladder Anomalies
- •Bladder Diverticula
- •Bladder Extrophy
- •Gonadal Development
- •Testicular Differentiation
- •Ovarian Differentiation
- •Gonadal Anomalies
- •Genital Duct System
- •Disorders of Testicular Function
- •Female Ductal Development
- •Prostatic Urethral Valves
- •Gonadal Duct Anomalies
- •External Genital Development
- •Male External Genital Development
- •Female External Genital Development
- •Anomalies of the External Genitalia
- •References
- •2: Gross and Laparoscopic Anatomy of the Upper Urinary Tract and Retroperitoneum
- •Overview
- •The Kidneys
- •The Renal Vasculature
- •The Renal Collecting System
- •The Ureters
- •Retroperitoneal Lymphatics
- •Retroperitoneal Nerves
- •The Adrenal Glands
- •References
- •3: Gross and Laparoscopic Anatomy of the Lower Urinary Tract and Pelvis
- •Introduction
- •Female Pelvis
- •Male Pelvis
- •Pelvic Floor
- •Urinary Bladder
- •Urethra
- •Male Urethra
- •Female Urethra
- •Sphincter Mechanisms
- •The Bladder Neck Component
- •The Urethral Wall Component
- •The External Urethral Sphincter
- •Summary
- •References
- •4: Anatomy of the Male Reproductive System
- •Testis and Scrotum
- •Spermatogenesis
- •Hormonal Regulation of Spermatogenesis
- •Genetic Regulation of Spermatogenesis
- •Epididymis and Ductus Deferens
- •Accessory Sex Glands
- •Prostate
- •Seminal Vesicles
- •Bulbourethral Glands
- •Penis
- •Erection and Ejaculation
- •References
- •5: Imaging of the Upper Tracts
- •Anatomy of the Upper Tracts and Introduction to Imaging Modalities
- •Introduction
- •Renal Upper Tract Basic Anatomy
- •Modalities Used for Imaging the Upper Tracts
- •Ultrasound
- •Radiation Issues
- •Contrast Issues
- •Renal and Upper Tract Tumors
- •Benign Renal Tumors
- •Transitional Cell Carcinoma
- •Renal Mass Biopsy
- •Renal Stone Disease
- •Ultrasound
- •Plain Radiographs and IVU
- •Renal Cystic Disease
- •Benign Renal Cysts
- •Hereditary Renal Cystic Disease
- •Complex Renal Cysts
- •Renal Trauma
- •References
- •Introduction
- •Pathophysiology
- •Susceptibility and Resistance
- •Epidemiological Breakpoints
- •Clinical Breakpoints
- •Pharmacodynamic Parameters
- •Pharmacokinetic Parameters
- •Fosfomycin
- •Nitrofurantoin
- •Pivmecillinam
- •b-Lactam-Antibiotics
- •Penicillins
- •Cephalosporins
- •Carbapenems
- •Aminoglycosides
- •Fluoroquinolones
- •Trimethoprim, Cotrimoxazole
- •Glycopeptides
- •Linezolid
- •Conclusion
- •References
- •7: An Overview of Renal Physiology
- •Introduction
- •Body Fluid Compartments
- •Regulation of Potassium Balance
- •Regulation of Acid–Base Balance
- •Diuretics
- •Suggested Reading
- •8: Ureteral Physiology and Pharmacology
- •Ureteral Anatomy
- •Modulation of Peristalsis
- •Ureteral Pharmacology
- •Conclusion
- •References
- •Introduction
- •Afferent Signaling Pathways
- •Efferent Signaling
- •Parasympathetic Nerves
- •Sympathetic Nerves
- •Vesico-Spinal-Vesical Micturition Reflex
- •Peripheral Targets
- •Afferent Signaling Mechanisms
- •Urothelium
- •Myocytes
- •Cholinergic Receptors
- •Muscarinic Receptors
- •Nicotinic Receptors
- •Adrenergic Receptors (ARs)
- •a-Adrenoceptors
- •b-Adrenoceptors
- •Transient Receptor Potential (TRP) Receptors
- •Phosphodiesterases (PDEs)
- •CNS Targets
- •Opioid Receptors
- •Serotonin (5-HT) Mechanisms
- •g-Amino Butyric Acid (GABA) Mechanisms
- •Gabapentin
- •Neurokinin and Neurokinin Receptors
- •Summary
- •References
- •10: Pharmacology of Sexual Function
- •Introduction
- •Sexual Desire/Arousal
- •Endocrinology
- •Steroids in the Male
- •Steroids in the Female
- •Neurohormones
- •Neurotransmitters
- •Dopamine
- •Serotonin
- •Pharmacological Strategies
- •CNS Drugs
- •Enzyme-inducing Antiepileptic Drugs
- •Erectile Function
- •Ejaculatory Function
- •Premature Ejaculation
- •Abnormal Ejaculation
- •Conclusions
- •References
- •Epidemiology
- •Calcium-Based Urolithiasis
- •Uric Acid Urolithiasis
- •Infectious Urolithiasis
- •Cystine-Based Urolithiasis
- •Aims
- •Who Deserves Metabolic Evaluation?
- •Metabolic Workup for Stone Producers
- •Medical History and Physical Examination
- •Stone Analysis
- •Serum Chemistry
- •Urine Evaluation
- •Urine Cultures
- •Urinalysis
- •Twenty-Four Hour Urine Collections
- •Radiologic Imaging
- •Medical Management
- •Conservative Management
- •Increased Fluid Intake
- •Citrus Juices
- •Dietary Restrictions
- •Restricted Oxalate Diet
- •Conservative Measures
- •Selective Medical Therapy
- •Absorptive Hypercalciuria
- •Thiazide
- •Orthophosphate
- •Renal Hypercalciuria
- •Primary Hyperparathyroidism
- •Hyperuricosuric Calcium Oxalate Nephrolithiasis
- •Enteric Hyperoxaluria
- •Hypocitraturic Calcium Oxalate Nephrolithiasis
- •Distal Renal Tubular Acidosis
- •Chronic Diarrheal States
- •Thiazide-Induced Hypocitraturia
- •Idiopathic Hypocitraturic Calcium Oxalate Nephrolithiasis
- •Hypomagnesiuric Calcium Nephrolithiasis
- •Gouty Diathesis
- •Cystinuria
- •Infection Lithiasis
- •Summary
- •References
- •12: Molecular Biology for Urologists
- •Introduction
- •Inherited Changes in Cancer Cells
- •VEGR and Cell Signaling
- •Targeting mTOR
- •Conclusion
- •References
- •13: Chemotherapeutic Agents for Urologic Oncology
- •Introduction
- •Bladder Cancer
- •Muscle Invasive Bladder Cancer
- •Metastatic Bladder Cancer
- •Conclusion
- •Prostate Cancer
- •Other Chemotherapeutic Drugs or Combinations for Treating HRPC
- •Conclusion
- •Renal Cell Carcinoma
- •Chemotherapy
- •Immunotherapy
- •Angiogenesis Inhibitor Drugs
- •Conclusion
- •Testicular Cancer
- •Stage I Seminoma
- •Stage I non-seminomatous Germ Cell Tumours (NSGCT)
- •Metastatic Germ Cell Tumours
- •Low-Volume Metastatic Disease (Stage II A/B)
- •Advanced Metastatic Disease
- •Salvage Chemotherapy for Relapsed or Refractory Disease
- •Conclusion
- •Penile Cancer
- •Side Effects of Chemotherapy
- •Conclusion
- •References
- •14: Tumor and Transplant Immunology
- •Antibodies
- •Cytotoxic and T-helper Cells
- •Immunosuppression
- •Induction Therapy
- •Maintenance Therapy
- •Rejection
- •Posttransplant Lymphoproliferative Disease
- •Summary
- •References
- •15: Pathophysiology of Renal Obstruction
- •Causes of Renal Obstruction
- •Effects on Prenatal Development
- •Prenatal Hydronephrosis
- •Spectrum of Renal Abnormalities
- •Renal Functional Changes
- •Renal Growth/Counterbalance
- •Vascular Changes
- •Inflammatory Mediators
- •Glomerular Development Changes
- •Mechanical Stretch of Renal Tubules
- •Unilateral Versus Bilateral
- •Limitations of Animal Models
- •Future Research
- •Issues in Patient Management
- •Diagnostic Imaging
- •Ultrasound
- •Intravenous Urography
- •Antegrade Urography and the Whitaker Test
- •Nuclear Renography
- •Computed Tomography
- •Magnetic Resonance Urography
- •Hypertension
- •Postobstructive Diuresis
- •References
- •Introduction
- •The Normal Lower Urinary Tract
- •Anatomy
- •Storage Function
- •Voiding Function
- •Neural Control
- •Symptoms
- •Flow Rate and Post-void Residual
- •Voiding Cystometry
- •Male
- •Female
- •Neurourology
- •Conclusions
- •References
- •17: Urologic Endocrinology
- •The Testis
- •Normal Androgen Metabolism
- •Epidemiological Aspects
- •Prostate
- •Brain
- •Muscle Mass and Adipose Tissue
- •Bones
- •Ematopoiesis
- •Metabolism
- •Cardiovascular System
- •Clinical Assessment
- •Biochemical Assessment
- •Treatment Modalities
- •Oral Preparations
- •Parenteral Preparations
- •Transdermal Preparations
- •Side Effects and Treatment Monitoring
- •Body Composition
- •Cognitive Decline
- •Bone Metabolism
- •The Kidneys
- •Endocrine Functions of the Kidney
- •Erythropoietin
- •Calcitriol
- •Renin
- •Paraneoplastic Syndromes
- •Hypercalcemia
- •Hypertension
- •Polycythemia
- •Other Endocrine Abnormalities
- •References
- •General Physiology
- •Prostate Innervation
- •Summary
- •References
- •Wound Healing
- •Inflammation
- •Proliferation
- •Remodeling
- •Principles of Plastic Surgery
- •Tissue Characteristics
- •Grafts
- •Flap
- •References
- •Lower Urinary Tract Symptoms
- •Storage Phase
- •Voiding Phase
- •Return to Storage Phase
- •Urodynamic Parameters
- •Urodynamic Techniques
- •Volume Voided Charts
- •Pad Testing
- •Typical Test Schedule
- •Uroflowmetry
- •Post Voiding Residual
- •Further Diagnostic Evaluation of Patients
- •Cystometry with or Without Video
- •Cystometry
- •Videocystometrography (Cystometry + Cystourethrography)
- •Cystometric Findings
- •Comment:
- •Measurements During the Storage Phase:
- •Measurements During the Voiding Phase:
- •Abnormal Function
- •Disorders of Sensation
- •Causes of Hypersensitive Bladder Sensation
- •Causes of Hyposensitive Bladder Sensation
- •Disorders of Detrusor Motor Function
- •Bladder Outflow Tract Dysfunction
- •Detrusor–Urethral Dyssynergia
- •Detrusor–Bladder Neck Dyssynergia
- •Detrusor–Sphincter Dyssynergia
- •Complex Urodynamic Investigation
- •Urethral Pressure Measurement
- •Technique
- •Neurophysiological Evaluation
- •Conclusion
- •References
- •Endoscopy
- •Cystourethroscopy
- •Ureteroscopy and Ureteropyeloscopy
- •Nephroscopy
- •Virtual Reality Simulators
- •Lasers
- •Clinical Application of Lasers
- •Condylomata Acuminata
- •Urolithiasis
- •Benign Prostatic Hyperplasia
- •Ureteral and Urethral Strictures
- •Conclusion
- •References
- •Introduction
- •The Prostatitis Syndromes
- •The Scope of the Problem
- •Category III CP/CPPS
- •The Goal of Treatment
- •Conservative Management
- •Drug Therapy
- •Antibiotics
- •Anti-inflammatories
- •Alpha blockers
- •Hormone Therapies
- •Phytotherapies
- •Analgesics, muscle relaxants and neuromodulators
- •Surgery
- •A Practical Management Plan
- •References
- •Orchitis
- •Definition and Etiology
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation
- •Treatment of Infectious Orchitis
- •Epididymitis
- •Definition and Etiology
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation of Epididymitis
- •Treatment of Acute Epididymitis
- •Treatment of Chronic Epididymitis
- •Treatment of Spermatic Cord Torsion
- •Fournier’s Gangrene
- •Definition and Etiology
- •Risk Factors
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation
- •Treatment
- •References
- •Fungal Infections
- •Candidiasis
- •Aspergillosis
- •Cryptococcosis
- •Blastomycosis
- •Coccidioidomycosis
- •Histoplasmosis
- •Radiographic Findings
- •Treatment
- •Tuberculosis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Schistosomiasis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Filariasis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Onchocerciasis
- •References
- •25: Sexually Transmitted Infections
- •Introduction
- •STIs Associated with Genital Ulcers
- •Herpes Simplex Virus
- •Diagnosis
- •Treatment
- •Chancroid
- •Diagnosis
- •Treatment
- •Syphilis
- •Diagnosis
- •Treatment
- •Lymphogranuloma Venereum
- •Diagnosis
- •Treatment
- •Chlamydia
- •Diagnosis
- •Treatment
- •Gonorrhea
- •Diagnosis
- •Treatment
- •Trichomoniasis
- •Diagnosis
- •Treatment
- •Human Papilloma Virus
- •Diagnosis
- •Treatment
- •Scabies
- •Diagnosis
- •Treatment
- •References
- •26: Hematuria: Evaluation and Management
- •Introduction
- •Classification of Hematuria
- •Macroscopic Hematuria
- •Microscopic Hematuria
- •Dipstick Hematuria
- •Pseudohematuria
- •Factitious Hematuria
- •Menstruation
- •Aetiology
- •Malignancy
- •Urinary Calculi
- •Infection and Inflammation
- •Benign Prostatic Hyperplasia
- •Trauma
- •Drugs
- •Nephrological Causes
- •Assessment
- •History
- •Examination
- •Investigations
- •Dipstick Urinalysis
- •Cytology
- •Molecular Tests
- •Blood Tests
- •Flexible Cystoscopy
- •Upper Urinary Tract Evaluation
- •Renal USS
- •KUB Abdominal X-Ray
- •Intravenous Urography (IVU)
- •Computed Tomography (CT)
- •Retrograde Urogram Studies
- •Magnetic Resonance Imaging (MRI)
- •Additional Tests and Renal Biopsy
- •Intractable Hematuria
- •Loin Pain Hematuria Syndrome
- •References
- •27: Benign Prostatic Hyperplasia (BPH)
- •Historical Background
- •Pathophysiology
- •Patient Assessment
- •Treatment of BPH
- •Watchful Waiting
- •Drug Therapy
- •Interventional Therapies
- •Conclusions
- •References
- •28: Practical Guidelines for the Treatment of Erectile Dysfunction and Peyronie´s Disease
- •Erectile Dysfunction
- •Introduction
- •Diagnosis
- •Basic Evaluation
- •Cardiovascular System and Sexual Activity
- •Optional Tests
- •Treatment
- •Medical Treatment
- •Oral Agents
- •Phosphodiesterase Type 5 (PDE 5) Inhibitors
- •Nonresponders to PDE5 Inhibitors
- •Apomorphine SL
- •Yohimbine
- •Intracavernosal and Intraurethral Therapy
- •Intracavernosal Injection (ICI) Therapy
- •Intraurethral Therapy
- •Vacuum Constriction Devices
- •Surgical Therapy
- •Conclusion
- •Peyronie´s Disease (PD)
- •Introduction
- •Oral Drug Therapy
- •Intralesional Drug Therapy
- •Iontophoresis
- •Radiation Therapy
- •Surgical Therapy
- •References
- •29: Premature Ejaculation
- •Introduction
- •Epidemiology
- •Defining Premature Ejaculation
- •Voluntary Control
- •Sexual Satisfaction
- •Distress
- •Psychosexual Counseling
- •Pharmacological Treatment
- •On-Demand Treatment with Tramadol
- •Topical Anesthetics
- •Phosphodiesterase Inhibitors
- •Surgery
- •Conclusion
- •References
- •30: The Role of Interventional Management for Urinary Tract Calculi
- •Contraindications to ESWL
- •Complications of ESWL
- •PCNL Access
- •Instrumentation for PCNL
- •Nephrostomy Drains Post PCNL
- •Contraindications to PCNL
- •Complications of PCNL
- •Semirigid Ureteroscopy
- •Flexible Ureteroscopy
- •Electrohydraulic Lithotripsy (EHL)
- •Ultrasound
- •Ballistic Lithotripsy
- •Laser Lithotripsy
- •Ureteric Stents
- •Staghorn Calculi
- •Lower Pole Stones
- •Horseshoe Kidneys and Stones
- •Calyceal Diverticula Stones
- •Stones and PUJ Obstruction
- •Treatment of Ureteric Colic
- •Medical Expulsive Therapy (MET)
- •Intervention for Ureteric Stones
- •Stones in Pregnancy
- •Morbid Obesity
- •References
- •Anatomy and Function
- •Pathophysiology
- •Management
- •Optical Urethrotomy/Dilatation
- •Urethral Stents
- •Preoperative Assessment
- •Urethroplasty
- •Anastomotic Urethroplasty
- •Substitution Urethroplasty
- •Grafts Versus Flaps
- •Oral Mucosal Grafts
- •Tissue Engineering
- •Graft Position
- •Conclusion
- •References
- •32: Urinary Incontinence
- •Epidemiology and Risk Factors
- •Pathophysiology
- •Urge Incontinence
- •Conservative Treatments
- •Pharmacotherapy
- •Invasive/ Surgical Therapies
- •Stress Urinary Incontinence
- •Male SUI Therapies
- •Female SUI Therapies
- •Mixed Urinary Incontinence
- •Conclusions
- •References
- •33: Neurogenic Bladder
- •Introduction
- •Examination and Diagnostic Tests
- •History and Physical Examination
- •Imaging
- •Urodynamics (UDS)
- •Evoked Potentials
- •Classifications
- •Somatic Pathways
- •Brain Lesions
- •Cerebrovascular Accident (CVA)
- •Parkinson’s Disease (PD)
- •Multiple Sclerosis
- •Huntington’s Disease
- •Dementias
- •Normal Pressure Hydrocephalus (NPH)
- •Tumors
- •Psychiatric Disorders
- •Spinal Lesions and Pathology
- •Intervertebral Disk Prolapse
- •Spinal Cord Injury (SCI)
- •Transverse Myelitis
- •Peripheral Neuropathies
- •Metabolic Neuropathies
- •Pelvic Surgery
- •Treatment
- •Summary
- •References
- •34: Pelvic Prolapse
- •Introduction
- •Epidemiology
- •Anatomy and Pathophysiology
- •Evaluation and Diagnosis
- •Outcome Measures
- •Imaging
- •Urodynamics
- •Indications for Management
- •Biosynthetics
- •Surgical Management
- •Anterior Compartment Repair
- •Uterine/Apical Prolapse
- •Enterocele Repair
- •Conclusion
- •References
- •35: Urinary Tract Fistula
- •Introduction
- •Urogynecologic Fistula
- •Vesicovaginal Fistula
- •Etiology and Risk Factors
- •Clinical Factors
- •Evaluation and Diagnosis
- •Pelvic Examination
- •Cystoscopy
- •Imaging
- •Treatment
- •Conservative Management
- •Surgical Management
- •Urethrovaginal Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Ureterovaginal Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Vesicouterine Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Uro-Enteric Fistula
- •Vesicoenteric Fistula
- •Pyeloenteric Fistula
- •Urethrorectal Fistula
- •References
- •36: Urologic Trauma
- •Introduction
- •Kidney
- •Expectant Management
- •Endovascular Therapy
- •Operative Intervention
- •Operative Management: Follow-up
- •Reno-Vascular Injuries
- •Pediatric Renal Injuries
- •Adrenal
- •Ureter
- •Diagnosis
- •Treatment
- •Delayed Diagnosis
- •Bladder and Posterior Urethra
- •Bladder Injuries: Initial Management
- •Bladder Injuries: Formal Repair
- •Anterior Urethral Trauma
- •Fractured Penis
- •Penile Amputation
- •Scrotal and Testicular Trauma
- •Imaging
- •CT-IVP (CT with Delayed Images)
- •Technique
- •Cystogram
- •Technique
- •Retrograde Urethrogram (RUG)
- •Technique
- •Retrograde Pyelogram (RPG)
- •Technique
- •One-Shot IVP
- •Technique
- •References
- •37: Bladder Cancer
- •Who Should Be Investigated?
- •Epidemiology
- •Risk Factors
- •Role of Screening
- •Signs and Symptoms
- •Imaging
- •Cystoscopy
- •Urine Tests
- •PDD-Assisted TUR
- •Pathology
- •NMIBC and Risk Groups
- •Intravesical Chemotherapy
- •Intravesical Immunotherapy
- •Immediate Cystectomy and CIS
- •Radical Cystectomy with Pelvic Lymph Node Dissection
- •sexual function-preserving techniques
- •Bladder-Preservation Treatments
- •Neoadjuvant Chemotherapy
- •Adjuvant Chemotherapy
- •Preoperative Radiotherapy
- •Follow-up After TUR in NMIBC
- •References
- •38: Prostate Cancer
- •Introduction
- •Epidemiology
- •Race
- •Geographic Variation
- •Risk Factors and Prevention
- •Family History
- •Diet and Lifestyle
- •Prevention
- •Screening and Diagnosis
- •Current Screening Recommendations
- •Biopsy
- •Pathology
- •Prognosis
- •Treatment of Prostate Cancer
- •Treatment for Localized Prostate Cancer (T1, T2)
- •Radical Prostatectomy
- •EBRT
- •IMRT
- •Brachytherapy
- •Treatment for Locally Advanced Prostate Cancer (T3, T4)
- •EBRT with ADT
- •Radical Prostatectomy
- •Androgen-Deprivation Therapy
- •Summary
- •References
- •39: The Management of Testis Cancer
- •Presentation and Diagnosis
- •Serum Tumor Markers
- •Primary Surgery
- •Testis Preserving Surgery
- •Risk Stratification
- •Surveillance Versus Primary RPLND
- •Primary RPLND
- •Adjuvant Treatment for High Risk
- •Clinical Stage 1 Seminoma
- •Risk-Stratified Adjuvant Treatment
- •Adjuvant Radiotherapy
- •Adjuvant Low Dose Chemotherapy
- •Primary Combination Chemotherapy
- •Late Toxicity
- •Salvage Strategies
- •Conclusion
- •References
- •Index
|
|
|
|
|
|
|
96 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Practical Urology: EssEntial PrinciPlEs and PracticE |
|
Table 6.1. groups and dosages of elected antibiotics for the |
nowadays mainly used in preventing recurrent |
|||||||
treatment of uncomplicated cystitis |
|
|
urinary tract infections in children and women.27 |
|||||
Antibiotic |
Antimicrobial |
Dosage/ |
|
Potential severe side effects with nitrofurantoin |
||||
groupsa |
|
substance |
duration |
|
were reported, such as lungand hepatotoxicity, |
|||
|
|
|
|
|
Oral |
|
especially in long-term usage.28 |
|
|
|
|
|
|
|
|
||
fosfomycines |
|
|
|
|
Pivmecillinam |
|||
|
|
|
fosfomycin |
3,000 mg/ |
||||
|
|
|
Pivmecillinam is a b-lactam antimicrobial that |
|||||
|
|
|
|
trometamol |
single dose |
|||
nitrofuranes |
|
|
|
|
has been used for the treatment of acute uncom- |
|||
|
|
|
|
plicated urinary infection for more than 20 years. |
||||
|
|
|
nitrofurantoin |
2 × 100 mg/ |
Pivmecillinam is the prodrug (ester) of mecilli- |
|||
|
|
|
|
retard |
5–7 days |
|
nam and shows no antibacterial activity until |
|
amidinopenicillins |
|
|
|
|
transformed into the active drug after absorp- |
|||
|
|
|
|
tion.29 Mecillinam is an amidine derivative of the |
||||
|
|
|
|
|
|
|
||
|
|
|
Pivmecillinam |
2 × 200 mg/ |
penicillin group. The mechanism of action differs |
|||
|
|
|
|
|
7 days |
|
slightly from other b-lactams, because it interacts |
|
acotrimoxazole and |
fluoroquinolones not regarded as |
first-line |
with the penicillin-binding protein 2.30 With a |
|||||
bioavailability of 60–75% it is well absorbed orally |
||||||||
agents. |
|
|
|
|
|
|||
|
|
|
|
|
and 45% are excreted in the urine.29 Mecillinam |
|||
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
has high activity against Gram-negative organ- |
|
Fosfomycin |
|
|
|
|
isms such as E. coli and other Enterobacteriaceae. |
|||
|
|
|
|
S. saprophyticus is considered resistant. |
||||
Fosfomycin acts as an analogue of phos- |
|
|||||||
phoenolpyruvate and forms a covalent bond |
Complicated and Nosocomially |
|||||||
with the active site cysteine residue (Cys 115) |
Acquired UTI |
|||||||
of UDP-N-acetylglucosamine enolpyruvyltrans- |
||||||||
ferase (MurA), which is a key enzyme of pepti- |
A wide variety of antibiotic agents is available |
|||||||
doglycan |
synthesis.22 |
It thus inhibits cell-wall |
||||||
for the treatment of complicated and nosocomi- |
||||||||
synthesis |
other |
than b-lactam |
antibiotics. |
|||||
ally acquired UTI (Table 6.2). The election of the |
||||||||
Fosfomycine tromethamine has approximately |
||||||||
antibiotics for treatment should follow regional |
||||||||
40% oral bioavailability and is primarily excreted |
||||||||
surveillance studies. Additionally, all substances |
||||||||
unchanged in the urine (approximately 90%).23 |
||||||||
suitable for treatment should be used in order to |
||||||||
The substance is active against Gram-positive |
||||||||
decrease the antibiotic pressure of individual |
||||||||
and Gram-negative |
bacteria, |
but |
shows |
|||||
substances. |
||||||||
decreased activity against M. morganii, P. vul- |
||||||||
|
garis, P. aeruginosa and E. faecium. |
b-Lactam-Antibiotics |
|
Nitrofurantoin
Nitrofurantoin belongs to the nitroheterocyclic compounds. The nitrogroup coupled onto the heterocyclic furan ring represents the proper site of effect. The nitrogroup is inactive and has to be activated by microbial nitroreductases after penetration into the microbial cell.24 Nitrofurantoin interferes with the carbohydrate metabolism. The bioavailability is about 90% and the urinary excretion is 40%.25 Susceptibility against E. coli is excellent,against gram-negative pathogens other than E. coli., like Klebsiella spp. or Enterobacter spp. reduced. There is no activity against Proteus spp. or P. aeruginosa.26 Nitrofurantoin is
b-Lactam antibiotics are chemically characterized by the presence of the b-lactam in the molecule, which is a cyclic amide forming a four-atom ring. All b-lactam antibiotics inhibit the bacterial cell wall synthesis by irreversible inhibition of the transpeptidases known as penicillin binding proteins. The b-lactam group includes three important families of antibiotics, which differ in the moiety fused to the b-lactam ring. The penicillins harbor a five-atom ring, a thiazolidine, the cephalosporins have a six-atom ring, a dihydrothiazine, and the carbapenems harbor a five-atom ring, in which the sulfur atom in position 1 of the structure has been replaced with a carbon atom.31
97
PrinciPlEs of BactErial Urinary tract infEctions and antimicroBials
Table 6.2 groups and dosages of elected antibiotics for the treatment of complicated Uti and uncomplicated pyelonephritis
Antibiotic groups |
Antimicrobial substance |
Dosage |
|
|
|
|
|
Oral |
I.V/I.M |
||
b-Lactams |
|
|
|
|
|
aminopenicillin + Bli |
ampicillin/sulbactam |
2 |
× 750 mg |
3 |
× 0.75–3 g |
|
amoxicillin/clavulanic acid |
2 |
× 1 g |
3 |
× 1.2–2.2 g |
acylureidopenicillin + Bli |
Piperacillin/tazobactam |
– |
3 |
× 2.5–4.5 g |
|
|
Piperacillin/combactam |
– |
3 |
× 5 g |
|
cephalosporin gr. 1 |
cephalexin |
for prophylaxis only |
– |
|
|
cephalosporin gr. 2 |
cefuroxime axetil |
2 |
× 250–500 mg |
– |
|
|
cefuroxime |
– |
3 |
× 0.75–1.5 g |
|
|
cefotiam |
– |
2–3 × 1–2 g |
||
cephalosporin gr. 3 |
cefpodoxim proxetile |
2 |
× 200 mg |
– |
|
|
ceftibuten |
1 |
× 200-400 mg |
– |
|
cephalosporin gr. 3a |
cefotaxime |
– |
2–3 × 1–2 g |
||
|
cetriaxone |
– |
1 |
× 1–2 g |
|
cephalosporin gr. 3b |
ceftazidime |
– |
2–3 × 1–2 g |
||
cephalosporin gr. 4 |
cefepime |
– |
2 |
× 2 g |
|
carbapenem gr. 1 |
imipenem |
– |
3 |
× 500 mg |
|
|
meropenem |
– |
3 |
× 500 mg |
|
carbapenem gr. 2 |
Ertapenem |
– |
1 |
× 400 mg |
|
fluoroquinolone gr. 2 |
ciprofloxacin |
2 |
× 500–750 mg |
2 |
× 400–600 mg |
fluoroquinolone gr. 3 |
levofloxacin |
1-2 × 500 mg |
1–2 × 500 mg |
||
Pyrimethamines |
|
|
|
|
|
trimethoprim |
|
2 |
× 200 mg |
|
|
trimethoprim + |
|
2 |
× 160 mg+ |
|
|
sulfamethoxazole |
|
2 |
× 800 mg |
|
|
aminoglycoside |
gentamicin |
– |
1 |
× 5–7 mg/Kg |
|
|
tobramycin |
– |
1 |
× 5–7 mg/Kg |
|
|
amikacin |
– |
1 |
× 15 mg/Kg |
|
Oxazolidinones |
|
|
|
|
|
oxazolidinone |
linezolid |
2 × 600 mg |
2 |
× 600 mg/kg |
|
Glycopeptides |
|
|
|
|
|
glycopeptide |
Vancomycin |
– |
2 |
× 1,000 mg |
|
|
teicoplanin |
– |
1 |
× 400 mg |
BLI beta-lactamase inhibitor; KG body weight.
98
Practical Urology: EssEntial PrinciPlEs and PracticE
Penicillins |
|
|
spectrum of activity and in potency against |
|||||||
Penicillins are classified mainly according to the |
Gram-negative bacilli.34 |
|
|
|
||||||
The first group |
cephalosporin cephalexin |
|||||||||
different chemical structures of the substituents |
||||||||||
harbors the phenylglycine side chain that is also |
||||||||||
at position 6 of the b-lactam molecule. |
|
|||||||||
|
encountered in the aminopenicillins.Cephalexin |
|||||||||
Penicillin G is primarily active against Gram |
||||||||||
is primarily active |
against staphylococci, but |
|||||||||
positive pathogens, if no resistance mechanisms |
||||||||||
less active against many Gram-negative bacte- |
||||||||||
have been acquired.31 |
|
|
||||||||
|
|
ria, because it is hydrolyzed by their b-lactama- |
||||||||
The aminopenicillins ampicillin and amoxi- |
||||||||||
ses. The bioavailability of cephalexin is about |
||||||||||
cillin feature the amino group, which confers |
||||||||||
90%, and the renal excretion is about 90% |
||||||||||
stability against amidase, an enzyme produced |
||||||||||
either.35 First group cephalosporins should how- |
||||||||||
by some Gram-negative bacteria that hydrolyzes |
ever not be used for the treatment of UTI, but |
|||||||||
the penicillin side chain, and stability against |
||||||||||
only for prophylaxis,because of the overall lower |
||||||||||
gastric acid. Oral absorption |
of ampicillin |
is |
||||||||
activities compared with second group cepha- |
||||||||||
approximately 50%, whereas |
amoxycillin |
is |
||||||||
losporins. |
|
|
|
|
|
|
||||
absorbed 90%. Urinary excretion of both antibi- |
|
|
|
|
|
|
||||
Second |
group |
cephalosporins |
such |
as |
||||||
otics is about 70%. The aminopenicillins ampi- |
||||||||||
cefuroxime and cefotiam show an increased |
||||||||||
cillin and amoxycillin are active against E. coli |
||||||||||
b-lactamase stability. This is mainly due to the |
||||||||||
and P. mirabilis, but almost |
inactive against |
oxime-group in cefuroxime and the thiazole- |
||||||||
other enterobacteria and totally inactive against |
||||||||||
amino group |
in cefotiam. After intravenous |
|||||||||
Pseudomonas spp. The aminopenicillins are not |
||||||||||
injection the renal excretion is 90% in cefu- |
||||||||||
stable against the b-lactamases frequently found |
||||||||||
roxime36 and 70% in cefotiam.37 In contrast to |
||||||||||
in S. aureus and many enterobacteria. Com- |
cefuroxime, the prodrug |
cefuroxime |
axetil |
is |
||||||
bination with a b-lactamase-inhibitor such as |
||||||||||
resorbed with a total bioavailability of 40% after |
||||||||||
clavulanic acid or sulbactam enhances Gram- |
||||||||||
rapid hydrolysis to the active parent compound, |
||||||||||
negative activity to a certain extent, but not |
||||||||||
cefuroxime.38 |
These |
cephalosporins |
show |
an |
||||||
against bacteria producing AmpC b-lactamases, |
enhanced activity against some Gram-negative |
|||||||||
such as Enterobacter spp. or Citrobacter spp.32 |
|
|||||||||
|
uropathogens. |
Against |
susceptible |
Gram- |
||||||
The acylamino (ureido)-penicillins, such as |
||||||||||
negative bacteria, second group cephalosporins |
||||||||||
piperacillin, own stronger polar groups on the |
||||||||||
are four to eight times more potent than first |
||||||||||
amino-group. However, the compound is not |
||||||||||
group compounds. There is no activity against |
||||||||||
stable against the b-lactamases of S. aureus and |
||||||||||
P. vulgaris, Morganella spp., Serratia spp., and |
||||||||||
some strains of Enterobacter spp. and Serratia |
||||||||||
P. aeruginosa. Cefotiam is more active against E. |
||||||||||
spp. Combination of piperacillin with the b-lac- |
||||||||||
coli, Klebsiella spp., and P. mirabilis than |
||||||||||
tamase inhibitor tazobactam |
can counteract |
|||||||||
cefuroxime. |
|
|
|
|
|
|||||
some of the b-lactamases increasingly produced |
|
|
|
|
|
|||||
Cephalosporins of the group 3a such as cefo- |
||||||||||
by Gram-negative bacteria. Urinary excretion of |
||||||||||
taxime and ceftriaxone, and the orally active |
||||||||||
both, piperacillin and tazobactam is approxi- |
||||||||||
substances cefpodoxime-proxetil and ceftibuten |
||||||||||
mately 70%. Piperacillin exhibits activity against |
||||||||||
exhibit a |
further increased activity against |
|||||||||
Pseudomonas spp. and Proteus vulgaris.33 |
|
|||||||||
|
Gram-negative organisms, because the side |
|||||||||
|
|
|
||||||||
|
|
|
chain protects the molecule from cephalos- |
|||||||
Cephalosporins |
|
|
porinases |
by |
steric hindrance.39 Cefotaxime |
|||||
|
|
is metabolized in about 30% to desacetyl- |
||||||||
|
|
|
||||||||
The cephalosporins are classified according to |
cefotaxime, which shows inferiorer antimicro- |
|||||||||
their primary route of administration (paren- |
biological activitiy.40 Ceftriaxone undergoes a |
|||||||||
teral vs. oral), and in groups according to their |
partial biliar excretion of about 45%.41 The bio- |
|||||||||
antibacterial spectrum. For structure activity |
availability of cefpodoxime-proxetil is about |
|||||||||
relationships, comparable characteristics can be |
40%,42 while the bioavailability of ceftibuten is |
|||||||||
seen as with penicillins. Substitutions at the side |
about 90%.43 The renal excretion rates are about |
|||||||||
chain mainly influence activity, whereas modifi- |
80%, 55%, 90%, and 90% for cefotaxime, ceftri- |
|||||||||
cations in position 3 of the nucleus influence |
axone, cefpodoxime, and ceftibuten, respec- |
|||||||||
mainly pharmacokinetics. The various groups |
tively.40-43 Third group cephalosporins are |
|||||||||
of cephalosporins differ from one another in the |
approximately ten times more active than the |